About: 'Trained immunity' from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 'Trained immunity' from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	'Trained immunity' from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes
Creator	Singh, K Singh, Samer Rakesh, ; Maurya, P Rajendra, ;
Source	MedRxiv
abstract	Protective variables for COVID-19 are unknown. 'Trained immunity' of the populace as a result of BCG policy implementation and coverage had been suggested to be one of the factors responsible for the differential impact of COVID-19 on different countries. Several trials are underway to evaluate the potential protective role of BCG vaccination in COVID-19. However, the lack of clarity on the use of appropriate controls concerning 'trained immunity' has been a cause of concern leading to more confusion as exemplified by a recently concluded trial in Israel that failed to find any correlation. Whereas, when we analyze the COVID-19 data of European countries without any mandatory BCG vaccination policy but with similar age distribution, comparable confounding variables, and the stage of the pandemic, the prevalence of Mycobacterium spp.(including BCG vaccine) exposure of the populations is consistently negatively correlated with COVID-19 infections per million population at all the time points evaluated [r(20): -0.5511 to -0.6338; p-value: 0.0118 to 0.0027]. The results indicate that the on-going and future studies evaluating the effect of BCG vaccination on COVID-19 outcomes should consider the inclusion of 'controls' for underlying 'trained immunity' prevalence or that resulting from the intervention (BCG vaccine) in such trials to arrive at more dependable conclusions.
has issue date	2020-07-14(xsd:dateTime)
bibo:doi	10.1101/2020.07.11.20151308
has license	medrxiv
sha1sum (hex)	030a53517e43dbf6b4ac2737d8c200cf66d9b205
schema:url	https://doi.org/10.1101/2020.07.11.20151308
resource representing a document's title	'Trained immunity' from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes
resource representing a document's body	covid:030a53517e43dbf6b4ac2737d8c200cf66d9b205#body_text
is schema:about of	named entity 'immunity' named entity 'points' named entity 'policy' named entity 'pandemic' named entity 'correlation' named entity 'failed' named entity 'comparable' named entity 'vaccination policy' named entity 'Israel' named entity 'differential' named entity 'leading' named entity 'p-value' named entity 'BCG vaccination' named entity 'immunization policy' named entity 'negatively correlated' named entity 'vaccination policy' named entity 'clinical trials' named entity 'medRxiv' named entity 'epidemiological' named entity 'infection' named entity 'Infection' named entity 'confounding variables' named entity 'BCG vaccination' named entity '1, 2' named entity 'Sensitivity Test' named entity 'active immunity' named entity 'JAMA' named entity 'JAMA' named entity 'mortality rates' named entity 'Institute for Health Metrics and Evaluation' named entity 'epidemic curve' named entity 'BCG' named entity 'COVID' named entity 'vaccination' named entity 'age distribution' named entity 'BCG' named entity 'COVID' named entity 'vaccination policy' named entity 'health infrastructure' named entity 'health infrastructure' named entity 'Vitamin' named entity 'Israel' named entity 'COVID' named entity 'confounding variables' named entity 'COVID-19' named entity 'confounding variables' named entity 'COVID-19' named entity 'CC-BY-NC 4.0' named entity 'HIV infection' named entity 'COVID' named entity 'LTBI' named entity 'immune response' named entity 'age distribution' named entity 'BCG vaccination' named entity 'Tuberculosis' named entity 'COVID' named entity 'coronavirus' named entity 'epidemic' named entity 'COVID-19' named entity 'APPROPRIATE' named entity 'PROTECTIVE ROLE' named entity 'ISRAEL' named entity 'STAGE' named entity 'COVID-19' named entity 'POTENTIAL' named entity 'VARIABLES' named entity 'AGE DISTRIBUTION' named entity 'Latent Tuberculosis' named entity 'Interferon Gamma Release Assay' named entity 'Mycobacterium spp' named entity 'BCG' named entity 'IGRA' named entity 'SARS-CoV-2' named entity 'pathogen' named entity 'CC-BY-NC 4.0' named entity 'Mycobacteria' named entity 'ethnicity' named entity 'BCG' named entity 'Tuberculin' named entity 'medRxiv' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software